Nanobiotix S.A. (NNBXF)
| Previous close | 9.10 |
| Open | 9.10 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 9.10 - 9.10 |
| 52-week range | 7.32 - 19.85 |
| Volume | |
| Avg. volume | 64 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, June 09, 2022--Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX):Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com
- Business Wire
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
PARIS & CAMBRIDGE, Mass., June 05, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatm
- Business Wire
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
PARIS & CAMBRIDGE, Mass., June 02, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022 at 9.30 AM Central European Time (CET), 3.30 AM Eastern Standard Time (EST), in the Company’s offices at 60 Rue de Wattignies (5th Floor) 75
